Raloxifene in breast cancer prevention.

Raloxifene is a benzothiophene, selective estrogen receptor modulator with estrogen-agonist effects in the skeleton and the cardiovascular system but estrogen-antagonist effects in the uterus and the mammary gland. This compound was first approved in different countries for the prevention and treatment of osteoporosis.
We performed a literature search to review available preclinical and clinical data that has led to the recent FDA approval of raloxifene as a chemopreventive agent for breast cancer in postmenopausal women.
Different placebo-controlled trials indicated that raloxifene is effective in reducing invasive breast cancer risk in postmenopausal women. In a recent comparative study, a similar efficacy between raloxifene and tamoxifen for breast cancer prevention was demonstrated, but raloxifene showed a more favorable safety profile.
AuthorsLuigi Gennari, Daniela Merlotti, Vincenzo De Paola, Ranuccio Nuti
JournalExpert opinion on drug safety (Expert Opin Drug Saf) Vol. 7 Issue 3 Pg. 259-70 (May 2008) ISSN: 1744-764X [Electronic] England
PMID18462184 (Publication Type: Journal Article, Review)
Chemical References
  • Anticarcinogenic Agents
  • Estrogen Antagonists
  • Selective Estrogen Receptor Modulators
  • Raloxifene Hydrochloride
  • Animals
  • Anticarcinogenic Agents (adverse effects, pharmacology, therapeutic use)
  • Breast Neoplasms (prevention & control)
  • Estrogen Antagonists (adverse effects, pharmacology, therapeutic use)
  • Female
  • Humans
  • Postmenopause
  • Raloxifene Hydrochloride (adverse effects, pharmacology, therapeutic use)
  • Selective Estrogen Receptor Modulators (adverse effects, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: